Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
US10273489B2 · kind B2 · utility
12Cited by
6References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 2, 2016 |
| Grant date | Apr 30, 2019 |
| Priority date | — |
| Expiry date | Mar 2, 2036 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.